Syncona — 2022 Investments
3 investments dated 2022 · listed companies and verified rows first · show all
Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.
BiotechDeep TechMedical DevicesEindhoven, US
Christian Ottmann(Executive Officer)Josh Seidenfeld(Executive Officer)Michelle Arkin(Director)Nancy Pryer(Executive Officer)Margarita Chavez(Director)Bryan Miller(Executive Officer)
Board seatRoel Bulthuis· per SEC Form D · $85M raise · filed Jun 2022
Co-investorsDroia VenturesMission BiocapitalMRL Ventures FundNextech InvestInkefRA Capital
BiotechCambridge, US
Robert Connelly(Executive Officer, Director)Garry Menzel(Executive Officer)Jeff Moore(Executive Officer)
BoardJohn Mendlein(Director)David Berry(Director)inNoubar Afeyan(Director)in
Board seatPaul Sekhri· per SEC Form D · $12M raise · filed Sep 2022
Co-investorsFlagship Pioneering
QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.
BiotechDeep TechMedical DevicesCambridge, US
Kevin Eggan(Co-founder)Roet(Co-founder)Woolf(Co-founder)Kasper Roet(Director, Executive Officer, Promoter)inShafique Virani(Executive Officer)Jason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)
Board seatRoel Bulthuis· per SEC Form D · $10M raise · filed Sep 2022
Co-investorsDroia VenturesMC Healthcare VenturesMission BiocapitalMitsui Global InvestmentSanofi VenturesSV Health Investors+7 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.